
News & Media

Featured
Oct 25, 2026
Cytonics joins Dr. Drew on Health Uncensored
Cytonics joins Dr. Drew to discuss the science behind CYT-108, our approach to osteoarthritis, and what’s next for the company. Watch the full conversation now!
Press Releases

09 Sep 2026
Cytonics Completes $4.8 Million Gross-Proceeds Financing Campaign
PR Newswire
Corporate
↗

30 Jun 2026
Cytonics Completes First-In-Human Phase 1 Clinical Study Report for CYT-108, Advancing Program Toward Next Phase of Development
PR Newswire
Clinical
↗

25 Mar 2025
Cytonics Announces Launch of Regulation A+ Equity Crowdfunding Campaign to Fund Phase 2 Development
PR Newswire
Corporate
↗

21 Jan 2025
Cytonics Announces Successful Completion of Phase 1 Study for First Nine Patients in CYT-108 Clinical Trial
PR Newswire
Clinical
↗
Videos
Featured video
CYT-108: Mechanism of Action

Cytonics: Engineering the Future of Joint Health with Molecular Precision

Mr. Wonderful Interviews Cytonics CEO Joey Bose: The Biotech Startup Taking on Big Pharma

Discover CYT-108’s “Venus Flytrap” Mechanism of Action

Why This Jiu Jitsu Icon Is Backing the Future of Osteoarthritis Treatment

Meet the Founder: How a Spine Surgeon and Jiu-Jitsu Black Belt Took on Osteoarthritis

Eve Gracie Talks Health, Healing, and Partnering with Cytonics
In the News
YouTube (Kevin O’Leary)
Mr. Wonderful Interviews Cytonics CEO Joey Bose
12 May 2025
Broadcast / video
Read on YouTube (Kevin O’Leary) ↗
Clinical Trials Arena
Cytonics concludes subject enrolment in Phase I knee osteoarthritis trial
09 Sep 2024
Article
Read on Clinical Trials Arena ↗
Clinical Trials Arena
Cytonics begins Phase I trial of new therapy to treat knee osteoarthritis
16 Jul 2024
Article
Read on Clinical Trials Arena ↗
The Clinical Trial Vanguard
Cytonics CYT-108: A Unique Approach to OA Treatment
11 Jan 2024
Interview
Read on The Clinical Trial Vanguard ↗
Crowdfund Insider
SeedInvest’s Largest Reg CF Offering Ever
Article
Read on Crowdfund Insider ↗
AllSci
A2M osteoarthritis clinical trial: Cytonics raises (headline unverified)
Article
Read on AllSci ↗
Events & Webinars
Upcoming
No upcoming events right now. Sign up for updates below and we’ll let you know.
Past

31 Jul 2025
Breaking the Pain Cycle
The Future of Joint Regeneration with Cytonics CEO Joey Bose
Zoom webinar

20 Jun 2025
Inside Cytonics
A Raw Conversation with CEO Joey Bose on Beating Osteoarthritis
Zoom webinar

12 May 2025
Biotech Meets the Bottom Line
Mr. Wonderful and Cytonics on Disrupting Osteoarthritis
YouTube
Media Inquiries
For interviews, press materials or collaboration opportunities, contact our team.
Get updates on CYT-108 and the science behind it.

The company is “testing the waters” of a potential offering which will be conducted under a valid exemption under U.S. Securities laws. No money or other consideration is being solicited, and if sent in response, will not be accepted. Reservations and/or indications of interest involve no obligation or commitment of any kind on any party. This process allows companies to determine whether there may be interest in an eventual offering of its securities. The company is not under any obligation to make an offering. It may choose to make an offering to some, but not all, of the people who indicate an interest in investing. If the company does go ahead with an offering, it will only be able to make sales after it has filed offering documents with the Securities and Exchange Commission (SEC). The information in those offering documents will be more complete than the information the company is providing now, and could differ in important ways. You must read the documents filed with the SEC before investing.
This website may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.
© 2026 Cytonics Corporation. All rights reserved.